May 01, 2019
The European Commission approved Zynquista (sotagliflozin) as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents the SGLT-1 and SGLT-2 proteins that impact how the intestines and kidneys absorb and glucose that will result in better diabetes control. Sanofi is collaborating ...
Read More...
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper